Search

Displaying results 2021 - 2030 of 4207 in total
  1. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  2. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate, or trichloroacetic acid, is a strong acid prepared by the reaction of chlorine with acetic acid in the presence of a suitable catalyst.

  3. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  4. Drug

    Trestolone

    go.drugbank.com/drugs/DB05830
    Investigational

    Trestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods.

  5. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].

  6. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  7. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    [L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology. … Sugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals.

  8. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  9. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  10. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.